Safety and immunogenicity of a respiratory syncytial virus fusion glycoprotein F subunit vaccine in healthy adults: Results of a phase 1, randomized, observer-blind, controlled, dosage-escalation study.
INTRODUCTION
Respiratory syncytial virus (RSV) is a leading cause of acute lower respiratory tract infections in infants. An investigational vaccine using an engineered recombinant RSV fusion glycoprotein in its post-fusion conformation (RSV F subunit vaccine) has been developed to protect young infants via maternal immunization. This first-in-human, phase I, observer-blind study (NCT02298179) evaluated the safety and immunogenicity of different dosages and formulations of RSV F subunit vaccine in healthy non-pregnant women and men aged 18-45 years.


METHODS
Participants were enrolled (1:1:1) in a stepwise dosage-escalation manner into three cohorts to receive RSV F subunit vaccine containing 45 µg, 90 µg and 135 μg of RSV F glycoprotein. Within each cohort, participants were randomized (1:1:1:1) to receive two doses of RSV F subunit vaccine with (aluminum hydroxide or MF59) or without adjuvant, or placebo, ≥28 days apart. Safety (until day 365 post-dose 2), anti-RSV neutralizing antibodies (NAbs) and serum total binding antibodies to RSV F protein (until day 181 post-dose 1) were evaluated.


RESULTS
All formulations were well-tolerated. No vaccine-related serious adverse events were reported. All participants were seropositive for anti-RSV NAbs at baseline, with geometric mean titers (GMTs) ranging from 184 (95% confidence interval [CI]: 127-266) to 380 (95% CI: 272-531). At 28 days post-dose 1, anti-RSV NAb GMTs in vaccine recipients ranged from 893 (95% CI: 702-1,136) to 1,602 (95% CI: 1,243-2,064). No booster effect was observed, but immune responses were maintained above pre-vaccination levels for six months post-dose 1. Ratios of RSV F total binding antibodies fold changes to NAb fold changes ranged from 2.79 to 4.12 at 28 days post-dose 1. The impact of the adjuvant was limited.


CONCLUSIONS
A single dose of each formulation of RSV subunit F vaccine was well-tolerated and enhanced preexisting NAb titers through six months of follow-up.
['Leroux-Roels|Geert|G|', 'De Boever|Fien|F|', 'Maes|Cathy|C|', 'Nguyen|Thi Lien-Anh|TL|', 'Baker|Sherryl|S|', 'Gonzalez Lopez|Antonio|A|']
D000293:Adolescent D000328:Adult D057134:Antibodies, Neutralizing D000914:Antibodies, Viral D001530:Belgium D005260:Female D006801:Humans D000071497:Immunogenicity, Vaccine D015994:Incidence D008297:Male D008875:Middle Aged D018357:Respiratory Syncytial Virus Infections D018113:Respiratory Syncytial Virus, Human D013997:Time Factors D014611:Vaccination D022223:Vaccines, Subunit D014760:Viral Fusion Proteins D014765:Viral Vaccines D055815:Young Adult
Safety Immunogenicity Respiratory syncytial virus Glycoprotein Subunit vaccine Adjuvant